JP2010525332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010525332A5 JP2010525332A5 JP2010504273A JP2010504273A JP2010525332A5 JP 2010525332 A5 JP2010525332 A5 JP 2010525332A5 JP 2010504273 A JP2010504273 A JP 2010504273A JP 2010504273 A JP2010504273 A JP 2010504273A JP 2010525332 A5 JP2010525332 A5 JP 2010525332A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarkers
- biomarker
- glucose
- measurement data
- adipoq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims description 603
- 238000000034 method Methods 0.000 claims description 153
- 206010012601 diabetes mellitus Diseases 0.000 claims description 85
- 238000005259 measurement Methods 0.000 claims description 84
- 102100031786 Adiponectin Human genes 0.000 claims description 56
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 claims description 51
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 48
- 239000008103 glucose Substances 0.000 claims description 48
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims description 47
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims description 47
- 102100040407 Heat shock 70 kDa protein 1B Human genes 0.000 claims description 42
- 101001037968 Homo sapiens Heat shock 70 kDa protein 1B Proteins 0.000 claims description 42
- 239000013256 coordination polymer Substances 0.000 claims description 42
- 102100023915 Insulin Human genes 0.000 claims description 30
- 239000012472 biological sample Substances 0.000 claims description 25
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 21
- 238000002405 diagnostic procedure Methods 0.000 claims description 11
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 8
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 102100020760 Ferritin heavy chain Human genes 0.000 claims description 3
- 101001002987 Homo sapiens Ferritin heavy chain Proteins 0.000 claims description 3
- 208000001280 Prediabetic State Diseases 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 2
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 claims description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 claims description 2
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000012549 training Methods 0.000 claims description 2
- 108010074051 C-Reactive Protein Proteins 0.000 claims 27
- 102100032752 C-reactive protein Human genes 0.000 claims 27
- 102000016267 Leptin Human genes 0.000 claims 27
- 108010092277 Leptin Proteins 0.000 claims 27
- 102000028416 insulin-like growth factor binding Human genes 0.000 claims 27
- 108091022911 insulin-like growth factor binding Proteins 0.000 claims 27
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 27
- 229940039781 leptin Drugs 0.000 claims 27
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 claims 5
- 108010076365 Adiponectin Proteins 0.000 claims 5
- 102000001554 Hemoglobins Human genes 0.000 claims 5
- 108010054147 Hemoglobins Proteins 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 101000690558 Streptomyces griseus A-factor receptor protein Proteins 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- 230000002608 insulinlike Effects 0.000 claims 5
- 101150037123 APOE gene Proteins 0.000 claims 1
- 102100029470 Apolipoprotein E Human genes 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 101001081567 Homo sapiens Insulin-like growth factor-binding protein 1 Proteins 0.000 description 28
- 102100027636 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 28
- 230000006872 improvement Effects 0.000 description 18
- 101001063991 Homo sapiens Leptin Proteins 0.000 description 13
- 102100030874 Leptin Human genes 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 6
- 150000002303 glucose derivatives Chemical class 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 102400000524 Fibrinogen alpha chain Human genes 0.000 description 3
- 101710137044 Fibrinogen alpha chain Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000008531 maintenance mechanism Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 229940119154 Neuropeptide Y receptor antagonist Drugs 0.000 description 1
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
- 229960004536 betahistine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- -1 troglidazone Chemical compound 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/788,260 US20070259377A1 (en) | 2005-10-11 | 2007-04-18 | Diabetes-associated markers and methods of use thereof |
| US11/788,260 | 2007-04-18 | ||
| US260907P | 2007-11-08 | 2007-11-08 | |
| US61/002,609 | 2007-11-08 | ||
| PCT/US2008/060830 WO2008131224A2 (en) | 2007-04-18 | 2008-04-18 | Diabetes-related biomarkers and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013013950A Division JP2013079981A (ja) | 2007-04-18 | 2013-01-29 | 糖尿病に関連するバイオマーカーおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010525332A JP2010525332A (ja) | 2010-07-22 |
| JP2010525332A5 true JP2010525332A5 (enExample) | 2011-06-02 |
| JP5271350B2 JP5271350B2 (ja) | 2013-08-21 |
Family
ID=39529374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010504273A Expired - Fee Related JP5271350B2 (ja) | 2007-04-18 | 2008-04-18 | 糖尿病に関連するバイオマーカーおよびその使用方法 |
| JP2013013950A Withdrawn JP2013079981A (ja) | 2007-04-18 | 2013-01-29 | 糖尿病に関連するバイオマーカーおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013013950A Withdrawn JP2013079981A (ja) | 2007-04-18 | 2013-01-29 | 糖尿病に関連するバイオマーカーおよびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (3) | EP2891885A3 (enExample) |
| JP (2) | JP5271350B2 (enExample) |
| CN (1) | CN102317786A (enExample) |
| AU (1) | AU2008242764B2 (enExample) |
| BR (1) | BRPI0810409A2 (enExample) |
| CA (1) | CA2684308A1 (enExample) |
| DK (1) | DK2147315T3 (enExample) |
| ES (1) | ES2434215T3 (enExample) |
| TW (1) | TW200849035A (enExample) |
| WO (1) | WO2008131224A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119358B2 (en) | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| US9817001B2 (en) | 2008-05-27 | 2017-11-14 | Boston Heart Diagnostics Corporation | Methods for determining LDL cholesterol treatment |
| JP2011528117A (ja) * | 2008-07-15 | 2011-11-10 | メタノミクス ヘルス ゲーエムベーハー | 胃バイパス及びそれに関連する状態を診断する手段及び方法 |
| US8762306B2 (en) | 2008-08-14 | 2014-06-24 | The University Of Toledo | Neural network for glucose therapy recommendation |
| US8470541B1 (en) | 2008-09-27 | 2013-06-25 | Boston Heart Diagnostics Corporation | Methods for separation and immuno-detection of biomolecules, and apparatus related thereto |
| WO2010146182A1 (en) * | 2009-06-19 | 2010-12-23 | Roche Diagnostics Gmbh | Method for monitoring the effect of ace inhibitor therapy on peripheral insulin resistance |
| BR112012004834A2 (pt) * | 2009-09-02 | 2018-03-13 | Univ Virginia Patent Foundation | acompanhar a probabilidade de hipoglicemia iminente em diabetes de dados de automonitiração de glicose no sangue (smbg) |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| JP2013509588A (ja) * | 2009-10-29 | 2013-03-14 | テシス バイオサイエンス， インコーポレイテッド | ２型糖尿病の予防に対して一貫した改善をもたらすタンパク質バイオマーカーおよび脂質代謝物バイオマーカー |
| US8775095B2 (en) | 2010-06-18 | 2014-07-08 | Roche Diagnostics Operations, Inc. | Methods and apparatus for decentralized diabetes monitoring |
| AU2012322018B2 (en) | 2011-10-13 | 2017-09-21 | Boston Heart Diagnostics | Compositions and methods for treating and preventing coronary heart disease |
| CN103376325A (zh) * | 2012-04-25 | 2013-10-30 | 中国科学院上海生命科学研究院 | 血管紧张素原蛋白前体作为肥胖型糖尿病标志物的应用 |
| WO2014055718A1 (en) * | 2012-10-04 | 2014-04-10 | Aptima, Inc. | Clinical support systems and methods |
| RU2015136673A (ru) * | 2013-01-31 | 2017-03-10 | Каприон Протеомикс Инк. | Биомаркеры сахарного диабета 2 типа и их применение |
| CN103198211B (zh) * | 2013-03-08 | 2017-02-22 | 北京理工大学 | 2型糖尿病发病危险因素对血糖影响的定量分析方法 |
| US9828624B2 (en) | 2013-07-24 | 2017-11-28 | Boston Heart Diagnostics Corporation | Driving patient compliance with therapy |
| CN104714022B (zh) * | 2013-12-12 | 2016-08-17 | 张曼 | 尿液纤维蛋白原α链在2型糖尿病合并冠心病中的应用 |
| AU2014364539B2 (en) * | 2013-12-20 | 2019-08-01 | Metabolon, Inc. | Biomarkers of de novo lipogenesis and methods using the same" (i.e. change Biomakers to Biomarkers) |
| CA2968221A1 (en) | 2014-11-17 | 2016-05-26 | Boston Heart Diagnostic Corporation | Cardiovascular disease risk assessment |
| EP3308291A4 (en) * | 2015-06-15 | 2019-03-20 | Kirontech Holding SAL | METHOD AND DEVICE FOR PROVIDING A PREDICTION |
| US11464456B2 (en) | 2015-08-07 | 2022-10-11 | Aptima, Inc. | Systems and methods to support medical therapy decisions |
| CN108289642B (zh) * | 2015-10-09 | 2021-02-23 | 迪诺威特公司 | 确定胰岛素疗法相关的参数、预测葡萄糖值和提供胰岛素给药建议的医学布置和方法 |
| CN105758984B (zh) * | 2015-12-15 | 2017-07-14 | 中国药科大学 | 衍生化hplc‑dad法测定药物中小分子卤代羧酸的方法 |
| CN106979982B (zh) * | 2016-01-19 | 2021-01-05 | 上海市第六人民医院 | 一种用于糖尿病风险预测、治疗评价的方法及试剂盒 |
| CN105567852A (zh) * | 2016-02-29 | 2016-05-11 | 北京泱深生物信息技术有限公司 | Iqce基因及其表达产物在i型糖尿病诊断中的用途 |
| CN105567851A (zh) * | 2016-02-29 | 2016-05-11 | 北京泱深生物信息技术有限公司 | 一种与糖尿病相关的分子标志物 |
| US10783801B1 (en) | 2016-12-21 | 2020-09-22 | Aptima, Inc. | Simulation based training system for measurement of team cognitive load to automatically customize simulation content |
| US20200124612A1 (en) * | 2017-04-11 | 2020-04-23 | University Of Iowa Research Foundation | Detection of predictors of preeclampsia |
| TWI682330B (zh) * | 2018-05-15 | 2020-01-11 | 美爾敦股份有限公司 | 自學式資料分類系統及方法 |
| CN108760706B (zh) * | 2018-06-08 | 2021-08-06 | 农业部环境保护科研监测所 | 一种快速筛选镉低积累水稻品种的方法 |
| CN109065174B (zh) * | 2018-07-27 | 2022-02-18 | 合肥工业大学 | 考虑相似约束的病历主题获取方法及装置 |
| EP3837286A4 (en) | 2018-08-16 | 2022-08-10 | The Johns Hopkins University | ANTIBODIES TO HUMAN ZNT8 |
| CN109559013A (zh) * | 2018-10-18 | 2019-04-02 | 深圳壹账通智能科技有限公司 | 基于小游戏的风险测试方法及装置、电子设备及可读存储介质 |
| CA3118297A1 (en) * | 2018-10-31 | 2020-05-07 | Better Therapeutics, Inc. | Systems, methods, and apparatuses for managing data for artificial intelligence software and mobile applications in digital health therapeutics |
| CN111378734A (zh) * | 2018-12-28 | 2020-07-07 | 康多富国际有限公司 | 新陈代谢疾病保健食品组合确定方法及其可读存储介质 |
| KR102839365B1 (ko) * | 2019-01-08 | 2025-07-29 | 일루리아 엘티디. | 주의력 결핍 과잉행동 장애 모니터링의 진단 및 효율성 |
| CN110231335A (zh) * | 2019-06-18 | 2019-09-13 | 济南大学 | 一种基于铁蛋白三维结构免疫传感器的制备方法及应用 |
| US12366570B2 (en) | 2019-10-01 | 2025-07-22 | The Johns Hopkins University | Cell-based ZNT8 assay |
| US20210153787A1 (en) * | 2019-11-26 | 2021-05-27 | Dexcom, Inc. | Recommendations based on continuous glucose monitoring |
| CN112881689B (zh) * | 2019-11-29 | 2023-02-10 | 张曼 | 尿液凝血因子ix蛋白及其多肽片段在正常妊娠或妊娠糖尿病中的应用 |
| CN112924682B (zh) * | 2019-12-05 | 2023-02-10 | 张曼 | 尿液纤维蛋白原α链蛋白及其多肽片段在正常妊娠中的应用 |
| CN112924675B (zh) * | 2019-12-05 | 2023-01-13 | 张曼 | 尿液胰腺甘油三酯脂肪酶蛋白及其多肽片段在正常妊娠中的应用 |
| CN111297329B (zh) * | 2020-02-24 | 2023-05-12 | 苏州大学 | 预测糖尿病患者心血管并发症动态发病风险的方法及系统 |
| CN114487431A (zh) * | 2020-11-12 | 2022-05-13 | 首都医科大学附属北京世纪坛医院 | 尿液α-2-HS-糖蛋白及其多肽片段在妊娠糖尿病中的应用 |
| TWI775253B (zh) * | 2020-12-24 | 2022-08-21 | 宏碁股份有限公司 | 高風險用藥路徑的計算方法 |
| CN114048374A (zh) * | 2021-10-28 | 2022-02-15 | 盐城金堤科技有限公司 | 待推荐对象的确定方法以及待推荐对象的确定装置 |
| WO2023084199A1 (en) * | 2021-11-09 | 2023-05-19 | Randox Laboratories Ltd. | Biomarkers of hidden obesity for use in preventative healthcare |
| WO2023102204A1 (en) * | 2021-12-03 | 2023-06-08 | The Trustees Of Indiana University | Biomarker for type 1 diabetes |
| CN115006536A (zh) * | 2022-04-19 | 2022-09-06 | 上海交通大学医学院附属瑞金医院 | Sgk1作为靶点在制备抑制肝糖异生药物中的应用 |
| CN114609395B (zh) * | 2022-04-25 | 2024-03-29 | 李玉凤 | 一种预测或诊断糖尿病或糖尿病肾病患者中的早期动脉粥样硬化的应用 |
| CN116631578B (zh) * | 2023-07-25 | 2023-10-13 | 山东硕杰医疗科技有限公司 | 一种肺癌网络综合管理信息平台 |
| WO2025117310A1 (en) * | 2023-12-01 | 2025-06-05 | Mars, Incorporated | Diabetes prognosis in a feline |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4302386A (en) | 1978-08-25 | 1981-11-24 | The Ohio State University | Antigenic modification of polypeptides |
| US4105776A (en) | 1976-06-21 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
| CA1178414A (en) | 1978-02-08 | 1984-11-27 | Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) | Packaging material having excellent seal packaging property |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| US4316906A (en) | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
| IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4508729A (en) | 1979-12-07 | 1985-04-02 | Adir | Substituted iminodiacids, their preparation and pharmaceutical compositions containing them |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4344949A (en) | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
| ZA817261B (en) | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
| US4337201A (en) | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
| US4410520A (en) | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
| GB2128984B (en) | 1982-05-12 | 1985-05-22 | Hoffmann La Roche | Diaza-bicyclic compounds |
| US4659678A (en) | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
| US4739073A (en) | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
| US4727022A (en) | 1984-03-14 | 1988-02-23 | Syntex (U.S.A.) Inc. | Methods for modulating ligand-receptor interactions and their application |
| US4780401A (en) | 1984-04-09 | 1988-10-25 | Ciba-Geigy Corporation | Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications |
| US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
| US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
| US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
| US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
| US4816463A (en) | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
| US4940727A (en) | 1986-06-23 | 1990-07-10 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
| US5116870A (en) | 1986-06-23 | 1992-05-26 | Merck & Co., Inc. | HMG-CoA reductase inhibitors |
| CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| US5018067A (en) | 1987-01-12 | 1991-05-21 | Iameter Incorporated | Apparatus and method for improved estimation of health resource consumption through use of diagnostic and/or procedure grouping and severity of illness indicators |
| US4772684A (en) | 1987-01-20 | 1988-09-20 | Triton Biosciences, Inc. | Peptides affecting blood pressure regulation |
| US5017716A (en) | 1987-05-22 | 1991-05-21 | E.R. Squibb & Sons, Inc. | Phosphorous-containing HMG-CoA reductase inhibitors, new intermediates and method |
| US5091378A (en) | 1987-05-22 | 1992-02-25 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method |
| US4904646A (en) | 1987-05-22 | 1990-02-27 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-COA reductase inhibitors |
| US4997837A (en) | 1987-09-08 | 1991-03-05 | Warner-Lambert Company | 6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
| US4906624A (en) | 1987-09-08 | 1990-03-06 | Warner-Lambert Company | 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
| US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
| US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
| US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
| US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
| US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
| US4929620A (en) | 1987-12-10 | 1990-05-29 | Warner-Lambert Company | 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis |
| US4939143A (en) | 1987-12-21 | 1990-07-03 | Rorer Pharmaceutical Corporation | Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors |
| US5001128A (en) | 1987-12-21 | 1991-03-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | HMG-COA reductase inhibitors |
| US4994494A (en) | 1987-12-21 | 1991-02-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | HMG-COA reductase inhibitors |
| US5001144A (en) | 1987-12-21 | 1991-03-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors |
| US4900754A (en) | 1987-12-21 | 1990-02-13 | Rorer Pharmaceutical Corp. | HMG-COA reductase inhibitors |
| US5081127A (en) | 1988-01-07 | 1992-01-14 | E. I. Du Pont De Nemours And Company | Substituted 1,2,3-triazole angiotensin II antagonists |
| US4946864A (en) | 1988-02-01 | 1990-08-07 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
| US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
| US5021453A (en) | 1988-03-02 | 1991-06-04 | Merck & Co., Inc. | 3-keto HMG-CoA reductase inhibitors |
| EP0331250B1 (en) | 1988-03-02 | 1994-04-13 | Merck & Co. Inc. | Antihypercholesterolemic agents |
| US4920109A (en) | 1988-04-18 | 1990-04-24 | Merck & Co., Inc. | Antifungal compositions and method of controlling mycotic infections |
| US5166171A (en) | 1988-05-13 | 1992-11-24 | Hoechst Aktiengesellschaft | 6-phenoxymethyl-4-hydroxytetrahydropyran-2-ones and 6-thiphenoxymethyl-4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, and in treating hypercholesterolemia |
| US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
| US4963538A (en) | 1988-06-29 | 1990-10-16 | Merck & Co., Inc. | 5-oxygenated HMG-CoA reductase inhibitors |
| US4897402A (en) | 1988-06-29 | 1990-01-30 | Merck & Co., Inc. | 5-oxa, 5-thia, 5-aza HmG-CoA reductase inhibitors |
| IT1226726B (it) | 1988-07-29 | 1991-02-05 | Zambon Spa | Composti attivi come inibitori della biosintesi del colesterolo. |
| US5196440A (en) | 1988-07-29 | 1993-03-23 | Zambon Group S.P.A. | Compounds active as inhibitors of the cholesterol biosynthesis |
| DE3832570A1 (de) | 1988-09-24 | 1990-03-29 | Hoechst Ag | 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte |
| DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| US4950675A (en) | 1988-12-21 | 1990-08-21 | Warner-Lambert Company | Pyridine di-mevalono-lactones as inhibitors of cholesterol biosynthesis |
| US4906657A (en) | 1988-12-21 | 1990-03-06 | Warner-Lambert Company | Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis |
| US4957940A (en) | 1988-12-21 | 1990-09-18 | Warner-Lambert Company | Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis |
| US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
| US4923861A (en) | 1989-02-07 | 1990-05-08 | Warner-Lambert Company | 6-(2-(2-(Substituted amino)-3-quinolinyl) ethenyl and ethyl) tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
| US5130306A (en) | 1989-03-13 | 1992-07-14 | Merck & Co., Inc. | 5-Oxygenated HMG-COA reductase inhibitors |
| US5132312A (en) | 1989-03-27 | 1992-07-21 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors |
| DE4004820A1 (de) | 1989-08-05 | 1991-04-25 | Bayer Ag | Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln |
| US5064825A (en) | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5102911A (en) | 1989-06-09 | 1992-04-07 | Merck & Co, Inc. | 4-Substituted HMG-CoA reductase inhibitors |
| US4970231A (en) | 1989-06-09 | 1990-11-13 | Merck & Co., Inc. | 4-substituted HMG-CoA reductase inhibitors |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
| US4992429A (en) | 1989-08-24 | 1991-02-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Novel HMG-COA reductase inhibitors |
| US5098931A (en) | 1989-08-31 | 1992-03-24 | Merck & Co., Inc. | 7-substituted HMG-CoA reductase inhibitors |
| US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US4946860A (en) | 1989-11-03 | 1990-08-07 | Rorer Pharmaceutical Corporation | Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors |
| US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| US5073566A (en) | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
| IT1237793B (it) | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
| US5025000A (en) | 1990-03-02 | 1991-06-18 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-CoA reductase inhibitor compounds |
| US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
| US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
| US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
| US5622985A (en) | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
| US5085992A (en) | 1990-07-19 | 1992-02-04 | Merck & Co., Inc. | Microbial transformation process for antihypertensive products |
| US5112857A (en) | 1990-09-04 | 1992-05-12 | Merck & Co., Inc. | Hmg-coa reductase inhibitor metabolites |
| US5087634A (en) | 1990-10-31 | 1992-02-11 | G. D. Searle & Co. | N-substituted imidazol-2-one compounds for treatment of circulatory disorders |
| US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
| US5182298A (en) | 1991-03-18 | 1993-01-26 | Merck & Co., Inc. | Cholesterol lowering agents |
| US5256689A (en) | 1991-05-10 | 1993-10-26 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5135935A (en) | 1991-05-17 | 1992-08-04 | Merck & Co., Inc. | Squalene synthetase inhibitors |
| US5250435A (en) | 1991-06-04 | 1993-10-05 | Merck & Co., Inc. | Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I) |
| US5202327A (en) | 1991-07-10 | 1993-04-13 | E. R. Squibb & Sons, Inc. | Phosphorus-containing hmg-coa reductase inhibitors |
| HU9203780D0 (en) | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| US5260332A (en) | 1992-02-07 | 1993-11-09 | Merci & Co., Inc. | Cholesterol lowering compounds |
| US5262435A (en) | 1992-02-10 | 1993-11-16 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5286895A (en) | 1992-02-19 | 1994-02-15 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5302604A (en) | 1992-03-09 | 1994-04-12 | Merck & Co., Inc. | Cholesterol lowering compounds produced by directed biosynthesis |
| US5369125A (en) | 1992-07-17 | 1994-11-29 | Merck & Co., Inc. | Cholesterol-lowering agents |
| US5283256A (en) | 1992-07-22 | 1994-02-01 | Merck & Co., Inc. | Cholesterol-lowering agents |
| US5317031A (en) | 1992-10-19 | 1994-05-31 | Merck & Co., Inc. | Cholesterol lowering compounds |
| US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
| US5543297A (en) | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| GB9602877D0 (en) | 1996-02-13 | 1996-04-10 | Merck Frosst Canada Inc | 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors |
| WO1995018799A1 (en) | 1994-01-10 | 1995-07-13 | Merck Frosst Canada Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| JPH10507765A (ja) | 1994-10-27 | 1998-07-28 | メルク フロスト カナダ インコーポレーテツド | シクロオキシゲナーゼ−２阻害剤として有用なスチルベン誘導体 |
| US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
| US5691374A (en) | 1995-05-18 | 1997-11-25 | Merck Frosst Canada Inc. | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
| US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
| US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
| US5643933A (en) | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| US5733909A (en) | 1996-02-01 | 1998-03-31 | Merck Frosst Canada, Inc. | Diphenyl stilbenes as prodrugs to COX-2 inhibitors |
| US5789413A (en) | 1996-02-01 | 1998-08-04 | Merck Frosst Canada, Inc. | Alkylated styrenes as prodrugs to COX-2 inhibitors |
| GB9607503D0 (en) | 1996-04-11 | 1996-06-12 | Merck Frosst Canada Inc | Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors |
| US5922742A (en) | 1996-04-23 | 1999-07-13 | Merck Frosst Canada | Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
| US5677318A (en) | 1996-07-11 | 1997-10-14 | Merck Frosst Canada, Inc. | Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents |
| US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| US20020038227A1 (en) | 2000-02-25 | 2002-03-28 | Fey Christopher T. | Method for centralized health data management |
| AU2002230848B2 (en) | 2000-12-14 | 2008-01-24 | The Brigham And Women's Hospital, Inc. | Inflammatory markers for detection and prevention of diabetes mellitus |
| US20040122296A1 (en) | 2002-12-18 | 2004-06-24 | John Hatlestad | Advanced patient management for triaging health-related data |
| US7468032B2 (en) | 2002-12-18 | 2008-12-23 | Cardiac Pacemakers, Inc. | Advanced patient management for identifying, displaying and assisting with correlating health-related data |
| US20040121305A1 (en) | 2002-12-18 | 2004-06-24 | Wiegand Roger Charles | Generation of efficacy, toxicity and disease signatures and methods of use thereof |
| WO2004088309A2 (en) | 2003-03-28 | 2004-10-14 | Cantata Laboratories, Inc. | Methods for diagnosing urinary tract and prostatic disorders |
| FI20050011L (fi) * | 2005-01-05 | 2006-07-06 | Jurilab Ltd Oy | Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi |
| US20070218519A1 (en) * | 2005-10-11 | 2007-09-20 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
| US20070259377A1 (en) | 2005-10-11 | 2007-11-08 | Mickey Urdea | Diabetes-associated markers and methods of use thereof |
| EP2407562A1 (en) * | 2006-05-08 | 2012-01-18 | Tethys Bioscience, Inc. | Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets |
-
2008
- 2008-04-18 EP EP14188942.8A patent/EP2891885A3/en not_active Withdrawn
- 2008-04-18 JP JP2010504273A patent/JP5271350B2/ja not_active Expired - Fee Related
- 2008-04-18 WO PCT/US2008/060830 patent/WO2008131224A2/en not_active Ceased
- 2008-04-18 ES ES08746276T patent/ES2434215T3/es active Active
- 2008-04-18 AU AU2008242764A patent/AU2008242764B2/en not_active Ceased
- 2008-04-18 CA CA002684308A patent/CA2684308A1/en not_active Abandoned
- 2008-04-18 TW TW097114417A patent/TW200849035A/zh unknown
- 2008-04-18 EP EP08746276.8A patent/EP2147315B1/en active Active
- 2008-04-18 DK DK08746276.8T patent/DK2147315T3/da active
- 2008-04-18 BR BRPI0810409-3A2A patent/BRPI0810409A2/pt not_active IP Right Cessation
- 2008-04-18 EP EP12175286.9A patent/EP2541254B1/en not_active Revoked
- 2008-04-18 CN CN2008800207230A patent/CN102317786A/zh active Pending
-
2013
- 2013-01-29 JP JP2013013950A patent/JP2013079981A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010525332A5 (enExample) | ||
| JP2020034573A (ja) | マルチマーカーリスク層別化 | |
| US11395621B2 (en) | Method for generating cognitive decline detection tool, method for measuring cognitive decline and tool for measuring same | |
| Holeman et al. | Patient-surgeon agreement in assessment of frailty, physical function, & social activity | |
| CN116779077A (zh) | 基于体检标志物构建生物学年龄及衰老评价的方法及系统 | |
| Mott et al. | Practice patterns in screening for metabolic disease in women with PCOS of diverse race-ethnic backgrounds | |
| JP5547639B2 (ja) | 診断マーカーの推定 | |
| KR100935610B1 (ko) | 허혈성 심장질환 발병 위험도 예측 장치 및 예측 방법과허혈성 심장질환 발병 위험도 예측 프로그램이 기록된 매체 | |
| Greenslade et al. | Examining renal impairment as a risk factor for acute coronary syndrome: a prospective observational study | |
| KR20090003406A (ko) | 중풍 발병 위험도 예측 장치 및 방법과 중풍 발병 위험도예측 프로그램이 기록된 매체 | |
| Schaffer et al. | Do orthostatic vital signs have utility in the evaluation of syncope? | |
| Tuncekin et al. | Investigation of the relationship between the measured alpha angle in capnography and readmission within thirty days in chronic obstructive pulmonary disease patients who presented to the emergency department | |
| West et al. | Observations and recommendations for community-based diabetes screenings | |
| RU2650212C1 (ru) | Способ оценки гипердиагностики инфаркта миокарда | |
| JP7736971B2 (ja) | 糖尿病境界域者のスクリーニング方法 | |
| Shingu et al. | A multicenter study of clinical predictors of positive pyrophosphate scintigraphy findings in the diagnosis of transthyretin amyloidosis | |
| RU2810369C1 (ru) | Способ определения темпа прогрессирования хронической болезни почек у пациентов с сахарным диабетом 2 типа с применением диагностического индекса снижения скорости клубочковой фильтрации | |
| Lima et al. | Validation of an Aerobic Fitness Questionnaire to estimate VO2 peak in a cohort of adult cardiac patients–Is it enough? | |
| CN113945723B (zh) | 预测免疫检查点抑制剂治疗相关肺炎发生风险的系统、储存介质及其应用 | |
| Hayat et al. | Evaluation of the Renin-Angiotensin Pathway in Paediatric Hypertension | |
| Itikhar | Obesity’s Impact on Pulmonary Hypertension Progression: A Cohort Study of Body Composition Metrics in UAE Population | |
| Naghipour | Samaneh Hosseinzadeh1, Zahra Khatirnamani2Ε, Enayatollah Bakhshi1, Alireza Heidari2 & | |
| Schultz et al. | Delays in Clinical Diagnosis of Hypertrophic Cardiomyopathy after Cardiovascular Imaging in Atrial Fibrillation | |
| Wang et al. | Development of a Blood-based Multiple-marker Screening Test for Hypertrophic Cardiomyopathy | |
| Li et al. | Diagnostic and prognostic value of troponins and natriuretic peptides in syncope: a systematic review and meta-analysis |